Skip to main content
$0.25 -$0.01 (-2.2%)

04:00 PM EST on 12/08/23

IsoRay, Inc. (NYSEMKT:ISR)

CAPS Rating: No stars

The Company develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases.

Current Price $0.25 Mkt Cap $70.1M
Open $0.26 P/E Ratio -2.69
Prev. Close $0.25 Div. (Yield) $0.00 (0.0%)
Daily Range $0.25 - $0.26 Volume 240,656
52-Wk Range $0.21 - $0.73 Avg. Daily Vol. 989,095

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

30 Outperform
12 Underperform
 

All-Star Players

1 Outperform
6 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NYSEMKT:ISR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Alacrity (< 20)
Submitted September 02, 2015

ISR a small medical device company, is already FDA approved and holds the paten, on Cesium-131 brachytherapy. ISR potentially cures cancer with outstanding results. MD Anderson, named the best cancer hospital, in America is now using the cesium-131.… More

TSIF (100.00)
Submitted June 24, 2014

This is my fourth time on this one after the spikes, averaging 15 points on each of the other three calls. Maybe it will bite me eventually, but as I've noted before, these ONE case, recycled Cesium news releases aren't an indication of revenue. They… More

Recent Community Commentary

Read the most recent pitches from players about ISR.

Recs

1
Member Avatar Alacrity (< 20) Submitted: 9/2/2015 1:31:13 PM : Outperform Start Price: $1.46 NYSE MKT:ISR Score: -219.78

ISR a small medical device company, is already FDA approved and holds the paten, on Cesium-131 brachytherapy. ISR potentially cures cancer with outstanding results. MD Anderson, named the best cancer hospital, in America is now using the cesium-131. MD Anderson will have the results on, November 7, 2015 . ISR earnings are on Sept 14, 2015, last quarter ISR beat the consensus. In May, CEO Dwight Babcock, commented on the small cell lung cancer result, the stock soared. A very negative press release was released by, Adam Feuerstein resulting in several law suits, the stock then plummeted. Given the outstanding results, of cesium 131 and the ability to cure cancer is a very positive indication this will soon be a winner. Thomson Reuters, just gave the stock a four star out of ten and expected price target of 25.00. I am long in ISR, and I am waiting for some very positive results.

Recs

0
Member Avatar JacksonFool805 (< 20) Submitted: 5/13/2014 5:08:55 PM : Outperform Start Price: $2.35 NYSE MKT:ISR Score: -231.64

They have a propriety cancer fighting treatment already FDA approved with a track record of over 80% effectiveness in patients. Up over 400% ytd and will continue to grow baby grow....

Recs

0
Member Avatar jpat34721 (22.11) Submitted: 5/6/2014 2:32:35 PM : Outperform Start Price: $2.56 NYSE MKT:ISR Score: -236.18

proprietary standard of care cancer therapy with proven results and expanding application.

Leaderboard

Find the members with the highest scoring picks in ISR.

No players have picked ISR yet. Tell us why you think ISR will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ISR.